NeXstar Applies Balm From Gilead
Executive Summary
Gilead Sciences began with, and then got rid of, programs in antisense in order to concentrate on nearer-term projects. NeXstar, too, tried to get rid of its oligonucleotide research by spinning it off into a separate company so as not to drag down the earnings of its product business. The market didn't care--and NeXstar chose to sell when Gilead came calling. Now Gilead's come full circle: With its acquisition of NeXstar, it's back into oligonucleotide research.
You may also be interested in...
Allogene Takes Step Closer To Off-The-Shelf CAR-Ts
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
New Testing Prompts New Finding Of NDMA, Cancer Risk In Metformin Products
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.
Need a specific report? 1000+ reports available
Buy Reports